Drug Approval | March 12, 2022
China approves BeiGene’s tislelizumab
Tislelizumab is now approved for seven indications in China
Tislelizumab is now approved for seven indications in China
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
The money will be donated to the United Nations Children’s Fund (UNICEF)
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts
The expansion is part of Lonza’s continued investment in its global manufacturing network, aiming to build a comprehensive offering for global customers
According to statistics, the global inhalation drug market reached US $ 25 billion in 2020
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Taisho Pharmaceutical will bring its experience and expertise in the research and development of therapeutic products to the collaboration.
High level of vaccine efficacy maintained over a 6-month period of surveillance
Subscribe To Our Newsletter & Stay Updated
